Diana Brainard, AlloVir CEO
February 15, 2023 11:26 AM EST
R&D
Cell/Gene Tx

AlloVir un­wraps PhII da­ta of cell ther­a­py in ex­pand­ed trans­plant in­di­ca­tion, leaves tri­al plans up in the air

Lei Lei Wu

News Reporter

AlloVir said its off-the-shelf cell ther­a­py re­duced the vi­ral load of BK virus in a greater per­cent­age of kid­ney trans­plant re­cip­i­ents com­pared to place­bo in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ex­clu­sive: Flag­ship-backed Va­lo Health los­es in­ter­im CEO ahead of key Phase 2 read­out

Edge­wise’s stock surges as heart drug pass­es ear­ly safe­ty test

FDA in­spec­tors dis­cov­er trucks car­ry­ing torn-up records leav­ing In­di­an gener­ics fac­to­ry

Stem cell start­up spun out of George Church’s lab rais­es $75M

Lasker Award goes to three sci­en­tists who pi­o­neered re­search be­hind GLP-1 drugs

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times